Skip to main content

TECH Bio-Techne Corporation

Healthcare

72.67 +0.01 +0.01% Close 11/2
Since 2024-12-02 -3.5%
Open
72.70
High
72.72
Low
72.67
Prev close
72.66
Volume
2M
Amplitude
0.07%
P/E
62.6
P/B
5.4
Revenue YoY (TTM)
-0.4%
52W 43.20 72.75

Is Bio-Techne Corporation a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Good, Growth: Good, Momentum: Good, Risk / liquidity: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but TTM P/E is Expensive.
TTM P/E 62.64 87th percentile Expensive
Price / book 5.4 84th percentile Expensive
Free-cash-flow yield (%) 2.31 55th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good All 3 indicators are Good.
ROE, TTM (%) 8.63 61th percentile Good
Operating margin, TTM (%) 20.73 73th percentile Good
FCF margin, TTM (%) 21.66 79th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Good Diluted EPS growth, TTM YoY is Top, but Revenue growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) -0.38 34th percentile Average
Diluted EPS growth, TTM YoY (%) 152.17 88th percentile Top
Momentum Good All 2 indicators are Good.
60-day return (%) 1.17 73th percentile Good
240-day return (%) 23.05 73th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Strong All 2 indicators are Top.
20-day dollar volume 201,711,109 92th percentile Top
60-day annualized volatility (%) 2.52 3th percentile Top
Factor Investing Explained: 10 Classic Factors in US Stocks

Bio-Techne Corporation (TECH) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Bio-Techne Corporation to every stock like it

AI finds several complementary traits of Bio-Techne Corporation across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Bio-Techne Corporation

Bio-Techne Corporation (TECH) peers and tracking

Watchlist

This page refreshes daily after the close. Add Bio-Techne Corporation to your watchlist to track signal changes on your next visit.

Bio-Techne Corporation (TECH) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

21 historical occurrences (since 2017-06-02)

Average forward return after 52-week adjusted-price high

20-day: Win 60%, Sample 20, Median +0.83%, Excess -0.16%, Beat mkt rate 35%

60-day: Win 73.7%, Sample 19, Median +5.98%, Excess +3.04%, Beat mkt rate 68.4%

120-day: Win 88.9%, Sample 18, Median +14.91%, Excess +8.54%, Beat mkt rate 72.2%

120 days after: historical avg +13.21%

20-day +1.33%
60-day +5.59%
120-day +13.21%
20-day
60-day
120-day
Win
60%
73.7%
88.9%
Sample
20
19
18
Median
+0.83%
+5.98%
+14.91%
Excess
-0.16%
+3.04%
+8.54%
Beat mkt rate
35%
68.4%
72.2%

Over 18 occurrences, 120-day forward avg gained 13.21%, beat the market by 8.54 pts; win rate 88.9%.

Top-quintile 6-month momentum

Active · now 85.14%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
20 historical occurrences (since 2016-07-05)

Average forward return after Top-quintile 6-month momentum

20-day: Win 52.6%, Sample 19, Median +0.21%, Excess -0.59%, Beat mkt rate 52.6%

60-day: Win 61.1%, Sample 18, Median +5.8%, Excess +0.73%, Beat mkt rate 55.6%

120-day: Win 66.7%, Sample 18, Median +2.64%, Excess -0.32%, Beat mkt rate 55.6%

120 days after: historical avg +8.14%

20-day +1.09%
60-day +5.6%
120-day +8.14%
20-day
60-day
120-day
Win
52.6%
61.1%
66.7%
Sample
19
18
18
Median
+0.21%
+5.8%
+2.64%
Excess
-0.59%
+0.73%
-0.32%
Beat mkt rate
52.6%
55.6%
55.6%

Over 18 occurrences, 120-day forward avg gained 8.14%, lagged the market by 0.32 pts; win rate 66.7%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 606+7.2% -3.5% 41.3% -15.2%
20-40 You are here325+14.1% +5.3% 54.2% -4.1%
40-60 153+38.1% +51.8% 72.5% +13.2%
60-80 92-18.9% -20.4% 2.2% -16.4%
80-100 363-2% -8.1% 44.6% -2%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 62.64, placing it in the 20.7 own-history percentile, inside the 20-40 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Now
-2.6%
Win rate 38.5% Excess -10.6%
480d
+18.9%
Win rate 86.3% Excess +5%
124d
+4.6%
Win rate 59.4% Excess +3.6%
288d
60-day momentum down
+11.2%
Win rate 65.6% Excess -0.7%
550d
+0.6%
Win rate 30.5% Excess -1.9%
82d
-12.2%
Win rate 13.3% Excess -2.8%
135d

Currently in “Cheap (own-history bottom third) × 60-day momentum up”: across 480 historical days, 120-day forward avg declined 2.6%, win rate 38.5%, lagged the market by 10.6%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

6 times historically; 60-day forward avg +3.95%, win rate 66.7%, beating the market by +2.24 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

18 times historically; 60-day forward avg +3.08%, win rate 61.1%, beating the market by -0.27 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.